Related by context. All words. (Click for frequent words.) 77 undergo percutaneous coronary 75 undergoing percutaneous coronary 73 primary percutaneous coronary 71 elective percutaneous coronary 69 PCI percutaneous coronary 67 patients undergoing percutaneous 66 underwent CABG 65 postintervention 65 patients undergoing CABG 64 unfractionated heparin UFH 64 venous thromboembolic disease 64 underwent surgical resection 64 nondiabetic patients 64 dalteparin 63 recurrent glioblastoma multiforme 63 PLX STROKE targeting 63 nadroparin 63 deep venous thromboses 63 preintervention 63 relapsed MM 63 bone marrow reticulin deposition 63 antiretroviral naïve 63 undergone radical prostatectomy 63 stage IIIb IV 63 underwent resection 62 ischemia driven 62 HBeAg negative patients 62 pancreatic resection 62 underwent coronary angiography 62 nicardipine 62 workhorse lesions 62 achieved CCyR 62 oral antidiabetic medication 62 noninvasive outpatient 62 Carotid Revascularization Endarterectomy vs. 62 pooled comparator 62 undergoing coronary angiography 62 glycoprotein IIb IIIa inhibitor 62 anthracycline taxane 61 refractory ischemia 61 Adjunctive 61 placebo dexamethasone 61 #mg/day [001] 61 ARCOXIA 61 symptomatic hyponatremia 61 undergoing coronary artery 61 reinfarction 61 resectable pancreatic cancer 61 Arch Intern Med 61 NMIBC 61 achieved ACR# 61 underwent liver transplantation 61 Coronary Artery Bypass Graft 61 VT VF 61 abacavir lamivudine 61 hepatorenal syndrome 61 revascularizations 61 myocardial infarction ventricular fibrillation 61 unstable angina pectoris 61 non splenectomized 61 HUNGARY NBH 2 61 arterial thromboembolic events 61 Folfox 61 oral hypoglycemic agent 61 Stent thrombosis 61 Val HeFT 61 antiretroviral naive 61 aspirin clopidogrel 61 IOP lowering 61 subcutaneous enoxaparin 61 fibrinolytic therapy 61 myelodysplastic myeloproliferative diseases 60 coronary intervention 60 nonmetastatic 60 prospective observational studies 60 mg administered orally 60 NATRECOR R 60 TAXUS Express2 60 acute STEMI 60 mg QD 60 sustained ventricular tachycardia 60 achieved sustained virologic 60 confirmed CCyR 60 angiographic outcomes 60 QTcF 60 de novo kidney transplant 60 GnRH agonist 60 glycoprotein IIb IIIa inhibitors 60 titrated glipizide 60 underwent radical cystectomy 60 recurrent DVT 60 mL/min/#.# m 2 60 atorvastatin #mg 60 acute myocardial infarctions 60 infliximab monotherapy 60 zoledronic acid Reclast 60 NSTE ACS 60 mitoxantrone plus 60 XIENCE V demonstrated 60 Percutaneous Transluminal Coronary Angioplasty 60 CMV seropositive 60 recurrent atrial fibrillation 60 TURBT 60 mcg QD 60 percutaneous transluminal coronary angioplasty 60 corticosteroid dose 60 MIRAPEX 59 azilsartan medoxomil 59 naïve HCV 59 recurrent VTE 59 RECORD1 59 angioplasty stenting 59 NSABP B 59 ug dose 59 paclitaxel eluting stents 59 thrombocytopenic 59 mild renal insufficiency 59 CLARITY study 59 #.#/#.# mmHg [001] 59 asymptomatic carotid stenosis 59 q#h 59 Angiographic 59 multicenter randomized controlled 59 DES implantation 59 non valvular atrial 59 prednisone prednisolone plus 59 desvenlafaxine succinate 59 β blocker 59 nucleoside naive 59 daily subcutaneous injections 59 alfuzosin 59 Postoperative complications 59 retrospectively analyzed 59 sirolimus stent 59 angioplasties stents 59 unresectable HCC 59 mild hepatic impairment 59 dyslipidemia hypertension diabetes 59 silent ischemia 59 coronary revascularization 59 LVSD 59 undergone splenectomy 59 undergoing cardiac catheterization 59 noncardiac 59 discontinued Viread 59 #mg QD [001] 59 antidepressants fluoxetine 59 Events MACE 59 catheter occlusion 59 certolizumab 59 insulin detemir 59 beta blockers ACE inhibitors 59 comparing XIENCE V 59 PRADAXA #mg 59 colorectal adenoma 59 evaluating tivozanib 59 -#.# log# copies mL 59 oral antidiabetes 59 FFR guided 59 ATACAND 59 receiving prophylactic anticoagulation 59 neutropenic sepsis 59 venlafaxine XR 59 undetectable HBV DNA 59 bypass graft CABG surgery 59 drug eluting stent implantation 59 perioperatively 59 hemodynamically significant 59 Edge STudy 59 tipranavir r 59 Acute Decompensated Heart Failure 59 FUSILEV enhances 58 symptomatic carotid stenosis 58 intravenous RSD# 58 TAXUS Express Stent 58 CALGB # [002] 58 FluCAM arm 58 primary patency 58 confidence interval #.#-#.# 58 BoNTA 58 perioperative mortality 58 cerebrovascular events 58 Acute Coronary Syndromes ACS 58 thromboembolic complications 58 morphometric vertebral fractures 58 insulin glulisine 58 receiving PEGINTRON 58 Operative mortality 58 mcg kg REBETOL 58 ® lenalidomide 58 low dose Iluvien 58 NOXAFIL Oral Suspension 58 Randomized controlled 58 coronary revascularisation 58 receiving INTRON 58 repeat revascularization 58 thromboembolisms 58 droperidol 58 atazanavir ritonavir 58 REYATAZ r arm 58 Mg Usa 58 N Engl J 58 carotid artery blockage 58 mcg linaclotide 58 atherosclerotic renal artery stenosis 58 Spectranetics laser 58 ACTEMRA TM 58 dose atorvastatin 58 rt PA 58 symptomatic intracranial 58 Myocardial Infarction Study 58 carotid artery stenting CAS 58 CIMZIA TM certolizumab pegol 58 maximally tolerated lipid lowering 58 unstable angina UA 58 elevated transaminases 58 postprocedure 58 achieved sustained virological 58 CABG surgeries 58 anastrazole 58 relapsing remitting MS RRMS 58 symptomatic VTE 58 5mg/kg 58 decompensated liver disease 58 postoperative AF 58 surgical revascularization 58 Percutaneous Coronary Intervention 58 adenoma recurrence 58 tirofiban 58 histologically confirmed 58 postoperative complication 58 inhospital 58 ARB telmisartan 58 severe exacerbations 58 IEQ kg 58 Tasigna prolongs 58 metastatic malignant 58 Accelerated Partial Breast Irradiation 58 treated nonsurgically 58 mg simvastatin 58 mcg BID 58 assessing T DM1 58 lung esophageal 58 #mg ATC 58 mg TID 58 reteplase 58 EXJADE 58 aripiprazole Abilify 58 endoscopic remission 58 TAXUS p value 58 EURIDIS 58 recurrent malignant glioma 58 APTIVUS r 58 HBeAg seroconversion 58 candesartan cilexetil 58 beta blocker therapy 58 graft occlusion 58 XIENCE V vs. 58 tenecteplase 58 oral rivaroxaban 58 retrospective cohort 58 pT3 58 serum estradiol 58 Unstable Angina 58 8mg/kg 58 cerebrovascular accidents 58 SORT OUT III 57 #mg QD [002] 57 patients undergoing noncardiac 57 clomipramine 57 mg ustekinumab 57 mg clopidogrel 57 CrCl 57 Drug eluting stent 57 quantitative coronary angiography 57 mg kg Hematide 57 mg subcutaneous 57 periprocedural 57 prospective nonrandomized 57 cisplatin gemcitabine 57 advanced adenoma 57 antiarrhythmic drug 57 PSADT 57 TEAEs 57 overt nephropathy 57 TAXUS paclitaxel eluting coronary 57 prospectively stratified 57 Doxil ® 57 Lipitor #mg 57 BR.# 57 conducted retrospective cohort 57 liver resection 57 HealthGrades analyzed 57 RLAI 57 Hazard Ratio 57 risperidone Risperdal 57 nonsignificant difference 57 revascularized 57 adenoidectomy 57 epoetin alpha 57 mcg albinterferon alfa 2b 57 containing abacavir 57 ACEI ARB 57 R entecavir 57 glycated hemoglobin levels 57 ischemic complications 57 CHAMPION PCI 57 NNT = 57 drotrecogin alfa activated 57 CYPHER Stent 57 prospectively evaluated 57 salmeterol fluticasone 57 defibrillator implantation 57 decompensated heart failure 57 ventricular tachyarrhythmia 57 coronary interventions 57 biochemical relapse 57 intravenous bolus 57 androgen suppression 57 ß blockers 57 double blinded randomized 57 argatroban 57 normotensive 57 % CI #.#-#.# [008] 57 TAXUS Stent 57 esophageal gastric 57 STRIDE PD 57 postoperative atrial fibrillation 57 deCODE AF TM 57 cerebral somatic oximeter 57 EEG abnormalities 57 Secondary endpoints included 57 multicentre prospective 57 lenalidomide Revlimid R 57 Cypher Sirolimus 57 sirolimus eluting 57 binary restenosis 57 cilostazol 57 TAXUS Liberte Long 57 Xelox 57 AML MDS 57 aspartate aminotransferase AST 57 ventricular tachycardia VT 57 flutamide 57 paroxysmal AF 57 preoperative chemotherapy 57 computed tomography angiography 57 prospectively enrolled 57 Severity MSCS score 57 nonfatal myocardial infarction MI 57 Study ARIC 57 defibrillator CRT D 57 LV dysfunction 57 Known hypersensitivity 57 preterm newborns 57 completely resected 57 severe hepatic dysfunction 57 Coronary Artery Bypass Grafting 57 oxycodone CR 57 prolonged QT interval 57 ipsilateral breast 57 saline placebo 57 dose escalation phase 57 #mg BID [003] 57 randomized #:#:# 57 highest tertile 57 bolus dose 57 Hypotension 57 KRAS mutations occur 57 HCV RESPOND 2 57 Intravitreal 57 gefitinib Iressa 57 tipranavir ritonavir 57 intracranial atherosclerosis 57 ratio ICER 57 ICD implants 57 reduce serum phosphate 57 IFN alfa 57 lipid lowering drugs 57 recurrent venous thromboembolism 57 atrioventricular block 57 nulliparous women 57 ipsilateral stroke 57 calcineurin inhibitor 57 ADHD stimulant 57 Clinically significant 56 UPPP 56 carotid surgery 56 iniparib BSI 56 mCi kg 56 hsCRP levels 56 AIR CF1 56 CaPSURE 56 lopinavir r arm 56 multicenter multinational 56 CI #.#-#.# [001] 56 endarterectomy 56 Am J Cardiol 56 left ventricular systolic 56 recurrent myocardial infarction 56 RRMS patients 56 β blockers 56 abnormal uterine growths 56 allogeneic HSCT 56 heFH 56 LMWH 56 #mg BID [001] 56 CI #.#-#.# [002] 56 receiving VICTRELIS 56 Erythropoietic therapies may 56 debulking surgery 56 placebo controlled Phase III 56 Subgroup analysis 56 underwent angiography 56 experienced virologic failure 56 LNG IUS 56 mm Stent 56 severe hypoglycemic 56 primary hypercholesterolemia 56 3mg/kg 56 glycated hemoglobin HbA1c 56 carotid revascularization 56 prespecified 56 GP IIb IIIa inhibitors 56 HBeAg positive patients 56 coronary artery bypass grafts 56 concomitant AEDs 56 NAVISTAR R 56 vessel renarrowing 56 de novo AML 56 lispro 56 clinically localized prostate 56 undergoing radical prostatectomy 56 PROMUS R 56 KRAS mutant tumors 56 EVEREST II 56 transarterial 56 ACE inhibitors beta blockers 56 Intravenous immunoglobulin 56 pretransplant 56 underwent prostate biopsy 56 plus GP IIb 56 definite stent thrombosis 56 % CI #.#-#.# [003] 56 clopidogrel Plavix 56 TDF FTC 56 doxazosin 56 nonobese 56 Cypher Stent 56 NYHA Class II 56 receiving XGEVA 56 ARIXTRA 56 ALT normalization 56 upper gastrointestinal bleeding 56 colorectal liver metastases 56 cardiovascular hospitalizations 56 randomized multicenter trial 56 ER CHOP 56 CCyR 56 neoadjuvant 56 bortezomib refractory 56 thymectomy 56 thromboembolic 56 annualized relapse 56 budesonide pMDI 56 cGy 56 ABSORB trial 56 everolimus eluting stents 56 Fasting blood glucose 56 undergoing peritoneal dialysis 56 adjunctive placebo 56 adalimumab Humira 56 Secondary endpoints include 56 chemoradiation therapy 56 carotid artery stenting 56 MADIT II 56 response CCyR 56 coronary bypass grafting 56 Thrombolysis 56 tolterodine ER 56 moderate renal impairment 56 baseline Hb 56 mmHg diastolic 56 haematologic 56 Platinol ® cisplatin 56 hereditary antithrombin deficient 56 TMC# r 56 Patients Undergoing 56 EDARBI 56 activated partial thromboplastin 56 postoperative chemotherapy 56 atherothrombotic events 56 vaginal hysterectomy 56 TAXUS ARRIVE 56 Radical prostatectomy 56 FOLFIRI alone 56 access graft VAG 56 #mg dosing group 56 inhaled budesonide 56 ritonavir boosted lopinavir 56 mg qd 56 mesilate 56 posttransplant 56 Randomized Evaluation 56 HIV uninfected 56 HIV HCV coinfected 56 asystole 56 Hypertensive adverse reactions 56 thoracoscopic lobectomy 56 ribavirin RBV 56 epirubicin cisplatin 56 evaluating REVLIMID 56 descending thoracic 56 CANCIDAS 56 pioglitazone hydrochloride 56 acute coronary syndromes ACS 56 HbA 1c levels 56 p = .# [002] 56 total abdominal hysterectomy 56 Prognostic significance 56 pregabalin Lyrica 56 circulating EPCs 56 Implantable Cardioverter Defibrillator ICD 56 hemoglobin A1c HbA1c 56 adverse perinatal 56 PSA nadir 55 weekly subcutaneous injections 55 segment binary restenosis 55 PASI scores 55 prescribed statins 55 bivalirudin alone 55 paroxysmal atrial fibrillation 55 erlotinib Tarceva ® 55 REVIVE Diabetes 55 BARACLUDE ® 55 microgram kg 55 metastatic GIST 55 nonfatal MI 55 NATRECOR ® 55 pravastatin Pravachol 55 percutaneous coronary interventions 55 retinal vein occlusion induced 55 intracerebral hemorrhage ICH 55 prescribed antipsychotics 55 endothelin antagonists 55 ARCALYST ® 55 rFVIIa 55 approved incretin mimetic 55 pyrimidine nucleoside analog 55 multivariable adjusted 55 sternal wound infections 55 nonvertebral fractures 55 rosuvastatin #mg 55 subcutaneous insulin 55 carotid endarterectomy CEA 55 aldosterone antagonist 55 cardiac resynchronisation therapy 55 BCIRG 55 prospectively randomized 55 observational cohort 55 coxib 55 Crohn Disease Activity 55 irinotecan cisplatin 55 Thal Dex 55 colon resections 55 serum phosphorous 55 systemic hypotension 55 allogeneic hematopoietic stem cell 55 onset atrial fibrillation 55 PREZISTA r arm 55 Coronary artery bypass grafting 55 oxycodone IR 55 Postmenopausal 55 bilateral oophorectomy 55 Forodesine HCl 55 Intra arterial 55 poor metabolizers 55 VELCADE melphalan 55 unfractionated heparin 55 revascularisation 55 multivessel disease 55 stable angina 55 coronary angiograms 55 Warfarin Coumadin 55 underwent radical prostatectomy 55 MACCE 55 repeat paracentesis 55 acute ischemic stroke 55 receiving SIMPONI 55 leukopenia pancytopenia thrombocytopenia 55 p = NS 55 esophageal resection 55 methotrexate monotherapy 55 asymptomatic PAD 55 NYHA functional class 55 evaluate ZFP Therapeutic 55 hyperlipidemia hypertension 55 mm Hg diastolic 55 ancrod 55 mycophenolic acid 55 Stenting Trial CREST 55 anaphylactic reactions bronchospasm 55 transrectal ultrasound guided 55 CYPHER R Sirolimus eluting 55 plus COPEGUS 55 elevated ALT 55 recurrent GBM 55 GetGoal Phase III 55 hematological parameters 55 Major Adverse Cardiac 55 myocardial infarction MI 55 PREZISTA ritonavir 55 Skin sterol 55 nadolol 55 infarction NSTEMI 55 thrombolytic therapy 55 autologous SCT 55 diameter stenosis 55 Pegylated Liposomal Doxorubicin 55 % CI #.#-#.# [007] 55 Phacoemulsification 55 IIIa inhibitor 55 aPTT 55 cardiac resynchronization 55 acute myocardial infarction AMI 55 baseline HbA1c 55 ejection fractions 55 Taxus Stent 55 Coronary artery bypass graft 55 receiving FUSILEV 55 FOLFOX4 55 lowest tertile 55 #:#-# [031] 55 plus prednisone 55 prospective observational 55 microbiologically evaluable 55 plus dexamethasone 55 biliary tract cancer 55 FOLFOX4 alone 55 CLL SLL 55 Ferinject R 55 serum creatinine levels 55 multicenter prospective 55 genitourinary GU 55 electrical cardioversion 55 Flu Cy 55 SpO2 pulse rate 55 intradermal injections 55 adefovir treated 55 advanced adenomas 55 achieved PASI 55 REALITY Trial 55 HIV coinfected 55 cystoid macular edema 55 Carotid endarterectomy 55 limiting generalizability 55 aged ≥ 55 HOMA IR 55 Teriflunomide 55 Temsirolimus 55 NSTEMI 55 mg RDEA# 55 relapsing multiple sclerosis 55 platelet aggregation inhibitor 55 glycosylated hemoglobin levels 55 Amgen Neulasta R 55 undergoing CABG 55 VICTOR E1 55 Index CDAI score 55 splenectomized 55 Rating Scale MADRS 55 thorough QT 55 MIST II 55 neutropenia dehydration dyspnea 55 alanine aminotransferase ALT 55 % Confidence Interval 55 biologic antibody 55 advanced neoplasia 55 blind multicenter 55 radical retropubic prostatectomy 55 Viread Emtriva Sustiva 55 reoperations 55 cyclophosphamide methotrexate 55 detemir 55 randomized blinded 55 x ULN 55 tenofovir emtricitabine 55 Intravitreal injections 55 treatment naïve genotype 55 ADCS CGIC 55 VBLOC TM 55 ICD therapy 55 undergoing elective 55 adenotonsillectomy 55 oral anticoagulation 55 postoperative mortality 55 phenytoin Dilantin 55 T1c 55 allogenic stem cell 55 detectable HCV RNA 55 idraparinux 55 retrospectively reviewed 55 abacavir Ziagen 55 generalized edema 55 valvular disease 55 #mg q8h 55 NovoLog ® Mix 55 meta regression 55 symptomatic BPH 55 TAXUS VI 54 hemoglobin A1c levels 54 urgent coronary revascularization 54 Transcatheter 54 concomitant antibiotics 54 revascularization procedure 54 intravenous cyclophosphamide 54 pegylated liposomal doxorubicin 54 accompanying electrolyte abnormalities 54 complete cytogenetic response 54 stage IIIB 54 recurrent ischemia 54 administered cetrorelix 54 tapentadol ER 54 hypertension diabetes mellitus 54 hip BMD 54 CARE HF 54 catheter angiography 54 mild renal impairment 54 mycophenolate mofetil MMF 54 recurrent UTI 54 undergoing coronary bypass 54 MADIT 54 ICD implantation 54 ticlopidine 54 directed thrombolysis 54 Neoadjuvant 54 postoperative delirium 54 perioperative complications 54 lipid lowering agents 54 COPERNICUS 54 sirolimus eluting stents 54 prospective observational cohort 54 Nesiritide 54 Primary endpoints 54 left ventricular dysfunction 54 diagnostic angiography 54 coronary artery bypass grafting 54 postoperative infections 54 coronary stenting 54 Acute Myocardial Infarction 54 reintervention 54 BENICAR HCT 54 sunitinib Sutent 54 baseline LDH 54 cardiopulmonary bypass CPB 54 peripheral arterial occlusive disease 54 prescribed antipsychotic 54 PROTECT II 54 irbesartan 54 evaluable subjects 54 antiplatelet medications 54 intravesical infusion therapy 54 receiving golimumab 54 NIASPAN 54 % CI #.#-#.# [006] 54 randomized multicenter 54 Raptiva r 54 patients receiving myelosuppressive 54 intravesical therapy 54 interstitial brachytherapy 54 interquartile range 54 nonobstructive CAD 54 venous thromboembolisms 54 plus glycoprotein IIb 54 target lesion revascularization 54 buprenorphine implants 54 steroid refractory 54 XIENCE V PROMUS Stent 54 Reduces Mortality 54 sacral nerve stimulation 54 System IPSS 54 Patency 54 estramustine 54 2 diabetes UKPDS 54 noninferior 54 lipid lowering therapy 54 peri procedural 54 lumbar spine BMD 54 Kaplan Meier estimates 54 variceal bleeding 54 acetonide FA 54 lanthanum carbonate 54 MGd 54 alanine aminotransferase 54 leucopenia 54 exocrine pancreatic insufficiency EPI 54 virologic failure 54 #mg/m# [002] 54 CABG surgery 54 unresectable recurrent 54 hemodialysis patients 54 doxorubicin cyclophosphamide 54 acute cholecystitis 54 Abciximab 54 COU AA 54 #mg/day [002] 54 MCyR 54 Raloxifene Evaluation MORE 54 losartan Cozaar 54 Scale EDSS 54 zotarolimus 54 statistically significant p = 54 IABP 54 Mean Symptom Complex 54 squamous histology 54 ascending aortic 54 aspirin beta blockers 54 SCIg 54 intravascular ultrasonography 54 renal scarring 54 prospective multicentre 54 laparoscopically assisted 54 transcranial Doppler ultrasound 54 Achieves Primary Endpoint 54 fasting triglyceride levels 54 neurologic complications 54 antirheumatic 54 Kaplan Meier analysis 54 IV tPA 54 Manobo tribal elders 54 rate CZECH NATIONAL 54 P = .# 54 treatment naive genotype 54 nonfatal myocardial infarction 54 resuscitated cardiac arrest 54 CHD CVD 54 bifurcated lesions 54 heparin induced thrombocytopenia 54 Complication rates 54 visilizumab 54 COPD exacerbation 54 undergo prostate biopsy 54 Free Survival PFS 54 acutely decompensated heart 54 olanzapine quetiapine 54 HbA1C levels 54 angiotensin converting enzyme inhibitor 54 EMPHASIS HF trial 54 golimumab CNTO 54 valve implantation 54 sirolimus eluting stent 54 Abbott bioabsorbable everolimus eluting 54 nucleotide analogue 54 achieved mucosal healing 54 percutaneous drainage 54 stratifying patients 54 Atypical Hemolytic Uremic Syndrome 54 PREZISTA r 54 mITT population 54 ADAS Cog 54 Helicobacter pylori eradication 54 postdischarge 54 Echocardiographic 54 Fasting plasma glucose 54 nonrandomized 54 -#.# mg dL [001] 54 noncardiovascular mortality 54 SSRI citalopram 54 video assisted thoracoscopic 54 insulin glargine rDNA origin 54 fallopian tube cancers 54 liver histology 54 Bare Metal Stent 54 conjugated equine estrogen 54 systolic dysfunction 54 octreotide LAR 54 oral olanzapine 54 operable breast cancer 54 Mg Uk 54 olanzapine LAI 54 Platinum Chromium 54 mg/m2 IV 54 Airway Bypass 54 PENTASA 54 beclomethasone dipropionate 54 antiarrhythmic drugs 54 patientswith 54 plasma creatinine 54 GOUT 54 lamotrigine 54 Sirolimus Eluting Coronary Stent 54 mg hydrochlorothiazide 54 placebo controlled dose escalation 54 OF POLAND NBP 54 intravenous iv 54 cisplatin vinorelbine 54 lipid lowering medications 54 antithymocyte globulin 54 seroconverted 54 thromboembolic events 54 placebo fluoxetine 54 pretest probability 54 CYP#A# substrate 54 metformin sulfonylureas 54 AGILECT R 54 NPH insulin 54 ximelagatran 54 placebo PBO 54 caspofungin 54 receiving highly emetogenic 54 REMINYL ® 54 Pegasys plus Copegus 54 ropivacaine 54 randomized controlled multicenter 54 ExTRACT TIMI 54 HbA1c levels 54 timepoints 54 nonischemic 54 subcutaneous methylnaltrexone 54 #mg dosing 54 CIMZIA ™ 54 comparator arm 54 placebo p = 54 events MACE 54 aortic crossclamp 54 GH deficiency 54 elective PCI 54 Vascugel ® 54 myocardial infarctions MIs 54 androgen ablation 54 dosing cohort 54 dose dexamethasone 54 allogeneic hematopoietic cell 54 nonobese patients 54 conventional angiography 54 estimated glomerular filtration 54 Navelbine R 54 cardiac repolarization 54 heavily pretreated 54 multicenter Phase III 54 Ishak fibrosis score 54 sulfonylurea metformin 54 antiepileptics 54 pyrexia mucositis sepsis febrile 54 systemic corticosteroid 53 REGENESIS Phase IIb 53 fallopian tube carcinoma 53 cytogenic 53 CYPHER ® 53 diabetes mellitus DM 53 bupropion XL 53 5 Fluorouracil 53 HES CEL 53 neurocognitive outcomes 53 angina myocardial infarction 53 pelvic lymphadenectomy 53 amoxicillin clavulanate 53 taxane therapy 53 tachyarrhythmias 53 Tarceva TM 53 uncoated stent 53 platelet aggregation inhibitors 53 Index CDAI 53 shortens systolic ejection 53 ALT elevation 53 IMPACT DCM trial 53 coinfected patients 53 Stenting Trial 53 CATIE AD 53 inotropic therapy 53 recurrent acute pancreatitis 53 DAS# scores 53 systemic embolism 53 R pramlintide acetate 53 zoledronate 53 superficial bladder cancer 53 AIR CF2 53 Tranexamic acid 53 corticosteroid induced 53 HIV treatments Reyataz 53 VIRAMUNE XR 53 oral FTY# 53 diagnostic catheterization 53 mg/m2 cohort 53 controlled multicenter 53 implantable cardioverter 53 divalproex sodium 53 parathyroidectomy 53 arterial stenosis 53 pulmonary artery banding 53 pegylated interferon alfa 2b 53 rehospitalization 53 PRoFESS 53 VTE prophylaxis 53 number NCT# ClinicalTrials.gov 53 beta carotene supplementation 53 relapsed refractory multiple myeloma 53 Castration Resistant Prostate Cancer 53 Montgomery Åsberg Depression